1204 related articles for article (PubMed ID: 30995972)
21. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial.
Muskiet MHA; Tonneijck L; Huang Y; Liu M; Saremi A; Heerspink HJL; van Raalte DH
Lancet Diabetes Endocrinol; 2018 Nov; 6(11):859-869. PubMed ID: 30292589
[TBL] [Abstract][Full Text] [Related]
22. Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure.
Smeijer JD; Koomen J; Kohan DE; McMurray JJV; Bakris GL; Correa-Rotter R; Hou FF; Januzzi JL; Kitzman DW; Kolansky DM; Makino H; Perkovic V; Tobe S; Parving HH; de Zeeuw D; Heerspink HJL
JACC Heart Fail; 2022 Jul; 10(7):498-507. PubMed ID: 35772861
[TBL] [Abstract][Full Text] [Related]
23. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Perkovic V; Jardine MJ; Neal B; Bompoint S; Heerspink HJL; Charytan DM; Edwards R; Agarwal R; Bakris G; Bull S; Cannon CP; Capuano G; Chu PL; de Zeeuw D; Greene T; Levin A; Pollock C; Wheeler DC; Yavin Y; Zhang H; Zinman B; Meininger G; Brenner BM; Mahaffey KW;
N Engl J Med; 2019 Jun; 380(24):2295-2306. PubMed ID: 30990260
[TBL] [Abstract][Full Text] [Related]
24. Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial.
Pratley RE; Cannon CP; Cherney DZI; Cosentino F; McGuire DK; Essex MN; Lawrence D; Jones PLS; Liu J; Adamsons I; Dagogo-Jack S
Lancet Healthy Longev; 2023 Apr; 4(4):e143-e154. PubMed ID: 37003273
[TBL] [Abstract][Full Text] [Related]
25. Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease.
Smeijer JD; Kohan DE; Rossing P; Correa-Rotter R; Liew A; Tang SCW; de Zeeuw D; Gansevoort RT; Ju W; Lambers Heerspink HJ
Cardiovasc Diabetol; 2023 Sep; 22(1):251. PubMed ID: 37716952
[TBL] [Abstract][Full Text] [Related]
26. Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease.
Chan KW; Smeijer JD; Schechter M; Jongs N; Vart P; Kohan DE; Gansevoort RT; Liew A; Tang SCW; Wanner C; de Zeeuw D; Heerspink HJL
Kidney Int; 2023 Dec; 104(6):1219-1226. PubMed ID: 37657768
[TBL] [Abstract][Full Text] [Related]
27. Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial.
Koomen JV; Stevens J; Bakris G; Correa-Rotter R; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray JJV; Parving HH; Perkovic V; Tobe SW; de Zeeuw D; Heerspink HJL
Diabetes Obes Metab; 2021 Feb; 23(2):561-568. PubMed ID: 33184931
[TBL] [Abstract][Full Text] [Related]
28. The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial.
de Zeeuw D; Bekker P; Henkel E; Hasslacher C; Gouni-Berthold I; Mehling H; Potarca A; Tesar V; Heerspink HJ; Schall TJ;
Lancet Diabetes Endocrinol; 2015 Sep; 3(9):687-96. PubMed ID: 26268910
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.
Mosenzon O; Blicher TM; Rosenlund S; Eriksson JW; Heller S; Hels OH; Pratley R; Sathyapalan T; Desouza C;
Lancet Diabetes Endocrinol; 2019 Jul; 7(7):515-527. PubMed ID: 31189517
[TBL] [Abstract][Full Text] [Related]
30. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
Heerspink HJL; Jongs N; Chertow GM; Langkilde AM; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Greene T;
Lancet Diabetes Endocrinol; 2021 Nov; 9(11):743-754. PubMed ID: 34619108
[TBL] [Abstract][Full Text] [Related]
31. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.
Cherney DZI; Dekkers CCJ; Barbour SJ; Cattran D; Abdul Gafor AH; Greasley PJ; Laverman GD; Lim SK; Di Tanna GL; Reich HN; Vervloet MG; Wong MG; Gansevoort RT; Heerspink HJL;
Lancet Diabetes Endocrinol; 2020 Jul; 8(7):582-593. PubMed ID: 32559474
[TBL] [Abstract][Full Text] [Related]
32. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
Mosenzon O; Wiviott SD; Cahn A; Rozenberg A; Yanuv I; Goodrich EL; Murphy SA; Heerspink HJL; Zelniker TA; Dwyer JP; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Kato ET; Gause-Nilsson IAM; Fredriksson M; Johansson PA; Langkilde AM; Sabatine MS; Raz I
Lancet Diabetes Endocrinol; 2019 Aug; 7(8):606-617. PubMed ID: 31196815
[TBL] [Abstract][Full Text] [Related]
33. Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy.
Kohan DE; Lambers Heerspink HJ; Coll B; Andress D; Brennan JJ; Kitzman DW; Correa-Rotter R; Makino H; Perkovic V; Hou FF; Remuzzi G; Tobe SW; Toto R; Parving HH; de Zeeuw D
Clin J Am Soc Nephrol; 2015 Sep; 10(9):1568-74. PubMed ID: 26153128
[TBL] [Abstract][Full Text] [Related]
34. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
Bakris GL; Agarwal R; Anker SD; Pitt B; Ruilope LM; Rossing P; Kolkhof P; Nowack C; Schloemer P; Joseph A; Filippatos G;
N Engl J Med; 2020 Dec; 383(23):2219-2229. PubMed ID: 33264825
[TBL] [Abstract][Full Text] [Related]
35. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
Heerspink HJL; Stefansson BV; Chertow GM; Correa-Rotter R; Greene T; Hou FF; Lindberg M; McMurray J; Rossing P; Toto R; Langkilde AM; Wheeler DC;
Nephrol Dial Transplant; 2020 Feb; 35(2):274-282. PubMed ID: 32030417
[TBL] [Abstract][Full Text] [Related]
36. Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial.
Cherney DZI; Charbonnel B; Cosentino F; Dagogo-Jack S; McGuire DK; Pratley R; Shih WJ; Frederich R; Maldonado M; Pong A; Cannon CP;
Diabetologia; 2021 Jun; 64(6):1256-1267. PubMed ID: 33665685
[TBL] [Abstract][Full Text] [Related]
37. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial.
Ando K; Ohtsu H; Uchida S; Kaname S; Arakawa Y; Fujita T;
Lancet Diabetes Endocrinol; 2014 Dec; 2(12):944-53. PubMed ID: 25466242
[TBL] [Abstract][Full Text] [Related]
38. Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial.
Parvanova A; Trillini M; Podestà MA; Iliev IP; Ruggiero B; Abbate M; Perna A; Peraro F; Diadei O; Rubis N; Gaspari F; Carrara F; Stucchi N; Belviso A; Bossi AC; Trevisan R; Remuzzi G; de Borst M; Ruggenenti P;
Lancet Diabetes Endocrinol; 2018 Jan; 6(1):27-40. PubMed ID: 29104158
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.
Tuttle KR; Hauske SJ; Canziani ME; Caramori ML; Cherney D; Cronin L; Heerspink HJL; Hugo C; Nangaku M; Rotter RC; Silva A; Shah SV; Sun Z; Urbach D; de Zeeuw D; Rossing P;
Lancet; 2024 Jan; 403(10424):379-390. PubMed ID: 38109916
[TBL] [Abstract][Full Text] [Related]
40. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.
de Zeeuw D; Agarwal R; Amdahl M; Audhya P; Coyne D; Garimella T; Parving HH; Pritchett Y; Remuzzi G; Ritz E; Andress D
Lancet; 2010 Nov; 376(9752):1543-51. PubMed ID: 21055801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
